Currently Viewing:
Newsroom
Currently Reading
FDA Approves Pegvaliase-pqpz to Treat Adults With Phenylketonuria
May 27, 2018 – Kelly Davio
Studies Evaluate Opioid and Preventive Treatment for Migraine
May 26, 2018 – Alison Rodriguez
Two Studies Evaluate Non-Tuberculous Mycobacterium Causes and Identification
May 25, 2018 – Alison Rodriguez
UnitedHealthcare, Quest Diagnostics Create Value-Based Care Arrangement for Laboratory Services
May 25, 2018 – Allison Inserro
Studies Investigate Exacerbations for Patients With COPD
May 25, 2018 – Alison Rodriguez
ADA Issues Recommendations Designed to Fix Insulin Pricing, Accessibility Crisis
May 25, 2018 – Allison Inserro
5 Abstracts to Look for at ASCO 2018
May 25, 2018 – Samantha DiGrande
This Week in Managed Care: May 25, 2018
May 25, 2018
AJMC® in the Press, May 25, 2018
May 25, 2018 – AJMC Staff

What We're Reading: HHS Cuts ACA Ads; Chemical Hazard in Houston; CAR-T Treatment Price Tag

AJMC Staff

HHS Is Slashing Spending on ACA Advertising

The Trump administration is cutting the advertising budget to promote enrollment under the Affordable Care Act (ACA) by 90%. According to The New York Times, the Obama administration spent $100 million last year advertising the beginning of open enrollment, but the new administration will only spend $10 million. HHS will also slash grants to groups that help people enroll in health plans offered by the ACA marketplaces. Officials cited the reasons for the cut funding as the falling number of first-time enrollees and failure of many navigator groups to meet enrollment targets despite the funding. However, proponents of the ACA are crying foul, claiming that the move is an attempt to make the law fail.

 

Chemical Plant Presents New Health Hazard in Houston

With flood waters from Hurricane Harvey damaging the refrigerating system at a chemical plant in Houston, people in the area are at risk of an airborne danger. The plant caught fire early Thursday morning, and, in a worst-case scenario, the gas released from it could cause harm to 1 million residents in a 23-mile radius, The Wall Street Journal reported. In reality, likely fewer than the 1 million people in the area would be affected—wind patterns and other weather factors will impact the effects. People who are exposed for 30 minutes to 1 hour would experience serious health effects.

 

Considering the High Price Tag of the first CAR-T Therapy

In an opinion piece for STAT, Anna Kaltenboeck and Peter B. Bach, MD, both of Memorial Sloan Kettering Cancer Center, discussed outcomes-based contracting for Novartis’ $475,000 CAR-T cell therapy recently approved by the FDA. They note that while Novartis said it will only charge when the drug achieves a clinical response, caution is needed. For example, Novartis can charge a much higher price in the first place or choose an outcome that makes the drug more likely to deliver a benefit. Another announcement from Novartis to keep an eye on is the idea that Kymriah may have a different price tag for any other indications it is approved for.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!